医学文献 >>
  • 检索发现
  • 增强检索
知识库 >>
  • 临床诊疗知识库
  • 中医药知识库
评价分析 >>
  • 机构
  • 作者
默认
×
热搜词:
换一批
论文 期刊
取消
高级检索

检索历史 清除

Venetoclax synergizes with gilteritinib in FLT3 wild-type high-risk acute myeloid leukemia by suppressing MCL-1.

广告
第一作者: Maike,Janssen
第一单位: Department of Internal Medicine V, Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany.;Molecular Medicine Partnership Unit (MMPU), University of Heidelberg and European Molecular Biology Laboratory, Heidelberg, Germany.
作者单位: Department of Internal Medicine V, Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany.;Molecular Medicine Partnership Unit (MMPU), University of Heidelberg and European Molecular Biology Laboratory, Heidelberg, Germany. [1] Department of Internal Medicine V, Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany. [2] Department of Internal Medicine V, Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany.;Molecular Medicine Partnership Unit (MMPU), University of Heidelberg and European Molecular Biology Laboratory, Heidelberg, Germany.;Division of Proteomics of Stem Cells and Cancer, German Cancer Research Center, Heidelberg, Germany. [3] Division of Stem Cells and Cancer, German Cancer Research Center, Heidelberg, Germany. [4] Department of Internal Medicine V, Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany.;Division of Stem Cells and Cancer, German Cancer Research Center, Heidelberg, Germany. [5] Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, United Kingdom.;Wellcome Trust-Medical Research Council Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom.;Department of Hematology, University of Cambridge, Cambridge, United Kingdom. [6] Department of Medicine I, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany. [7] Medical Clinic and Policlinic I, Hematology and Cellular Therapy, Leipzig University Hospital, Leipzig, Germany. [8] Department of Hematology and Oncology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany. [9] Hematology-Oncology, Department of Medicine II, Goethe University Hospital Frankfurt, Frankfurt am Main, Germany. [10] Research Unit Apoptosis in Hematopoietic Stem Cells, Helmholtz Zentrum München, German Research Center for Environmental Health, Munich, Germany.;German Cancer Consortium, Partner Site Munich, Munich, Germany. [11] Research Unit Apoptosis in Hematopoietic Stem Cells, Helmholtz Zentrum München, German Research Center for Environmental Health, Munich, Germany.;German Cancer Consortium, Partner Site Munich, Munich, Germany.;Department of Pediatrics, University Hospital, Ludwig Maximilian University, Munich, Germany. [12] Division of Proteomics of Stem Cells and Cancer, German Cancer Research Center, Heidelberg, Germany.;Medical Faculty, Heidelberg University, Heidelberg, Germany. [13]
DOI 10.1182/blood.2021014241
PMID 35857899
发布时间 2025-05-30
提交
  • 浏览79
Blood

Blood

2022年140卷24期

2594-2610页

相似文献

  • 中文期刊
  • 外文期刊
  • 学位论文
  • 会议论文

加载中!

加载中!

加载中!

加载中!

法律状态公告日 法律状态 法律状态信息

特别提示:本网站仅提供医学学术资源服务,不销售任何药品和器械,有关药品和器械的销售信息,请查阅其他网站。

  • 客服热线:4000-115-888 转3 (周一至周五:8:00至17:00)

  • |
  • 客服邮箱:yiyao@wanfangdata.com.cn

  • 违法和不良信息举报电话:4000-115-888,举报邮箱:problem@wanfangdata.com.cn,举报专区

官方微信
万方医学小程序
new医文AI 翻译 充值 订阅 收藏 移动端

官方微信

万方医学小程序

使用
帮助
Alternate Text
调查问卷